CDT Equity Expands IP Portfolio with Two Tapinarof Combination and Cocrystal Patents
CDT Equity filed two patent applications covering combination therapies pairing tapinarof with proven agents and novel cocrystal forms to underpin a second-generation product with improved formulation and efficacy. These IP additions aim to extend tapinarof’s lifecycle, broaden its clinical scope, and boost out-licensing potential across new skin disease areas.
1. Patent Filings Details
CDT Equity filed two patent applications covering a combination therapy pairing tapinarof with a class of clinically proven agents and novel cocrystal forms of tapinarof. These filings expand the company’s intellectual property portfolio by protecting second-generation formulation strategies.
2. Second-Generation Product Potential
The patented combination and cocrystal approaches are designed to underpin a new tapinarof product with enhanced formulation properties and potential efficacy benefits in psoriasis and atopic dermatitis.
3. Market Expansion and Out-Licensing
CDT Equity anticipates extending tapinarof’s lifecycle and broadening its addressable market into additional dermatological and orphan disease areas, while leveraging these patents to pursue out-licensing partnerships.